Research programme: GRB2 inhibitors - SUGENAlternative Names: GRB2 inhibitors research programme - SUGEN; Growth inhibitor factor receptor binding protein 2 inhibitors research programme - SUGEN
Latest Information Update: 28 Feb 2008
At a glance
- Originator SUGEN
- Mechanism of Action Apoptosis stimulants; Signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 21 Sep 1999 SUGEN has been acquired by Pharmacia & Upjohn
- 27 Nov 1998 Preclinical development for Cancer in USA (Unknown route)